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BACKGROUND: Imatinib induces responses and disease stabilisations in non-resectable patients with aggressive fibromatosis (AF).
The precise target of imatinib in AF and predictive factors for response to treatment are unknown.
METHODS: We investigated factors potentially predictive of response to imatinib in a series of 40 patients with progressive AF included
in a phase II trial of imatinib: we tested the presence of KIT exon 10 variant (M541L), the expression of imatinib-sensitive kinases and
cell cycle proteins by immunohistochemistry (IHC), and other clinical and biological factors.
RESULTS: Of 10 patients for whom DNA could be extracted, 3 had a KIT exon 10 variant (30%), with no correlation with response or
progression-free survival (PFS). The expression of other imatinib targets (PDGFRA/B, macrophage colony-stimulating factor receptor
(M-CSFR)) and of downstream components of the cell cycle, cell proliferation and proliferation pathway (cyclin D1, ERK, MEK 1–2)
did not correlate with PFS. Pre-treatment lymphopenia (o1500/ml) and tumour size 4120mm correlated with shorter PFS in
univariate and multivariate analyses.
CONCLUSION: Our findings show that a baseline biological characteristic of the patient is the major parameter influencing response to
imatinib in aggressive fibromatosis. Tumour characteristics, including the presence of a KIT exon 10 M541L variant, may influence
tumour control but this needs to be confirmed and better explained.
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Aggressive fibromatosis (AF), also known as desmoid tumour, is a
rare neoplasm arising from deep musculo-aponeurotic structures.
The disease, which affects 2 to 4 per 100000 persons annually, may
occur sporadically or be associated with familial adenomatous
polyposis in Gardner syndrome. This slow-growing fibrous
tumour may arise at any site in the body. Desmoid tumours have
been classified into three main subsets, according to their location:
extra-abdominal (60% of cases), abdominal wall (25%), and intra-
abdominal (15%) tumours. They are considered non-malignant,
with loco regional aggressiveness and a potential for recurrence
but no risk of metastatic spread (Nuyttens et al, 2000; Enzinger
and Weiss, 2001; Janinis et al, 2003).
When treatment is decided upon, complete surgical removal
remains the best option but may be difficult or mutilating,
depending on the tumour location or disease extension. Moreover,
a significant proportion of patients relapse locally and/or
regionally after initial surgery; in these patients, mutilating surgery
and/or radiotherapy are often used, with important functional
consequences in case of musculoskeletal or organ resection. When
local treatment is not feasible, systemic therapies including
hormonal treatments such as with anti-estrogens, administration
of non-steroidal anti-inflammatory drugsor chemotherapy may
induce responses, whereas some authors propose a watch and wait
policy (Fiore et al, 2009). Imatinib mesylate (Gleevec) is a specific
tyrosine-kinase inhibitor targeting kit, bcr-abl, platelet-derived
growth factor receptors and, as more recently reported, M-CSFR or
CSF1R. Responses and prolonged disease stabilisations with
imatinib have been reported in different series of patients with
relapsing AF, with 1-year progression-free survival (PFS) rates
close to 60–70% (Mace et al, 2002; Gonc¸alves et al, 2006; Heinrich
et al, 2006). However, the biological mechanisms underlying the
cytostatic effect of imatinib in AF remain unclear.
In this work, we analysed potential predictors of response to
imatinib in AF using samples from patients included in the phase
II study of the French Sarcoma Group, DESMINIB (Fayette et al,
2007; Dufresne et al, 2009). The presence of the M541L KIT
variant, the expression of imatinib targets and cell cycle proteins
on tissue microarrays (TMAs), as well as more classical clinical
and biological factors were investigated.
MATERIALS AND METHODS
Patients with progressive or recurrent AF not amenable to curative
surgery or radiotherapy were included in a phase II multicenter
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sstudy evaluating the efficacy and toxicity of imatinib. Patients with
adequate end-organ function were treated with a dose of 400mg
imatinib, increasing to 800mg in case of disease progression.
Best clinical response to imatinib (400 or 800mg daily) was
defined according to the RECIST criteria. Evaluation was carried
out every 3 months. All on-treatment tumour evaluations but two
were reviewed by an independent radiological review committee.
Patients whose best response was complete response (CR), partial
response (PR) or stable disease (SD) lasting more than 6 months
were considered responsive. Patients for whom disease stabilisa-
tion lasted less than 6 months or who had disease progression were
considered non-responsive. One of the secondary end points of the
study was the determination of clinical and biological criteria
potentially predictive of response or prolonged disease stabilisa-
tion on treatment with imatinib. Informed consent was obtained
from all patients before their enrolment in the study and collection
of archival pathology specimens.
In all, 40 patients were included in this study. Two patients who
participated in the initial clinical study refused consent for use of
their tumour samples for biological research. Paraffin-embedded
tissue samples from 34 of the 40 patients (85%) were collected
from the pathology centres.
Immunohistochemistry (IHC)
A total of 5 of the 34 tissue samples were not suitable for the
construction of TMAs. In all, 29 specimens were thus used as
donor blocks. Sections from each donor block were stained with
haematoxylin, eosin, and saffron. Morphologically representative
regions were located and circled on each slide. Finally, three 1mm
cylindrical cores were extracted from the circled areas and
precisely arrayed into new recipient paraffin blocks (35 22 
3mm), with a distance of 1.5mm between cores. TMA blocks were
cut into 4mm sections with a microtome.
Table 1 presents the different antibodies tested with their dilution,
the duration of antigen retrieval and the duration of incubation with
primary antibody. All reactions were realised using a BenchMark XT
automated stainer (Ventana, Tuscon, AZ, USA). All slides were
deparaffinised by heating at 751C for 16min. Antigen retrieval was
carried out by treatment with EDTA (pH 8.0) between 30 and 60min
at 951C. The samples were incubated for 24 or 32min at 371Cw i t ht h e
primary antibody, and then 8min at 371C with the secondary
antibody directly combined with horseradish peroxidase. All samples
were counterstained with haematoxylin.
Mutation analysis
We analysed the previously reported KIT exon 10 mutation
(Gonc¸alves et al, 2006), which corresponds to an A to C point
mutation (positions 1621 on mRNA and 69304 on DNA) resulting in
the substitution of methionine for leucine (position 541). Genomic
DNA was extracted from slides of 34 paraffin-embedded specimens
using the MasterPure complete DNA and RNA purification kit
(Epicentre, Madison, WI, USA). DNA of suitable quality for mutation
analysis was obtained in only 10 cases, mainly because of improper
fixation of paraffin-embedded tissues. Polymerase chain reaction
(PCR) was used to amplify KIT exon 10. The primers used were
generated by Invitrogen (Carlsbad, CA, USA): 50-GAG TGG CTG
TGG TAG AGA TC-30 (sense) and 30-GAG AAA GGG AAA AAT AGA
TCA-50 (antisense). PCR was carried out using Taq DNA polymerase
(Transgenomic, Omaha, NE, USA) with the following cycle
conditions: denaturation at 951C, followed by 10 cycles at decreasing
temperatures between 661Ca n d6 1 1C with a decrement of 0.51Cp e r
cycle, and additional extension at 721C. The primers used for
sequencing were the same as those used for amplification. Before
sequencing, PCR products were purified using Centriprep centrifugal
filter device (Millipore, Billerica, MA, USA). The purified PCR
product was then subjected to automated sequencing using a DNA
analyser (Applied Biosystem, Carlsbad, CA, USA).
Statistical analysis
The duration of PFS is defined as the time from the beginning of
treatment to the date of disease progression or death. PFS is
a continuous variable, censured at the date of disease progression
or death. PFS rates were estimated using the Kaplan–Meier
method and compared using the log-rank test. The Cox propor-
tional hazards model was used to identify the factors possibly
influencing the duration of PFS. Variables found significant in
univariate analysis were used for multivariate analysis.
Together with protein expression and presence of KIT muta-
tions, we assessed the following variables: gender, age, site of
primary tumour, tumour size, performance status (PS), number of
previous surgeries, PNN count, haemoglobin levels and lympho-
penia before imatinib.
RESULTS
Complete clinical results of the desminib phase II study are
currently being submitted for publication and will only be briefly
described here. Table 2 presents the major clinical data of the
study. In all, 40 patients, 12 (30%) males and 28 (70%) females,
with a median age of 41 years were included in the desminib phase
II trial between August 2004 and November 2005. In six cases
(15%), AF was associated with familial adenomatous polyposis.
Tumour sites were the limbs (n¼24, 60%), the abdominal wall
(n¼7, 18%), the mesentery (n¼8, 20%) and the head and neck
(n¼4, 10%). Previous treatments included surgery (n¼33, 80%),
radiotherapy (n¼9, 23%), hormonal treatment (n¼18, 45%),
non-steroidal anti-inflammatory drugs (n¼12, 30%), and
chemotherapy (n¼8, 20%). All patients had recurrent or
progressive disease at the time of inclusion. Imatinib was given
Table 1 Antibodies characteristics
Antibody Reference Dilution Ag retrieval (min) Primary Ab (min)
Anti-c-kit A4502; Dako, Glostrup, Denmark 1:100 30 24
Anti-PDGFR a AF 307 NA; R&D, Minneapolis, MN, USA 1:50 30 32
Anti-PDGFR b sc-339; Santa Cruz, Santa Cruz, CA, USA 1:300 30 32
Anti-M-CSFR 49C10; Cell Signaling, Danvers, MA, USA 1:50 30 32
Anti-E cadherin 18-0223; Zymed, Carlsbad, CA, USA 1:70 30 24
Anti-b catenin M3539; Dako 1:200 30 32
Anti-p42 map Kinase ERK 9108; Cell Signaling 1:100 30 32
Anti-phospho-AKT Ser 473 3787; Cell Signaling 1:50 30 32
Anti-phospho-MEK 1/2 2338; Cell Signaling 1:50 30 32
Anti-cyclin D1 RM-9104-R7; Neomarkers, Fremont, CA, USA 1 30 24
Abbreviations: Ab¼antibody; Ag¼antigen; ERK¼extracellular signal regulated kinase; M-CSFR¼macrophage colony-stimulating factor receptor; PDGFR¼platelet derived
growth factor.
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sfor 1 year at a dose of 400mg/day. With a median follow-up of 34
months, PFS at 2 years was 55% (95% CI 39-69), with 4 (10%)
patients in PR and 1 (2.5%) in CR (Fayette et al, 2007; Dufresne
et al, 2009). After dose-escalation, 8 out of 10 patients had a second
progression after transient stabilisation of their disease for a
median of 12 months (range 2–30).
Immunohistochemical analysis of the expression of KIT,
PDGFRA and B, M-CSFR, p42 ERK, phospho-Ser 473-Akt, phospho
MEK 1–2, and cyclin D1, b catenin and E-Cadherin was performed
on TMA. PDGFRB and b catenin were found expressed in all
samples, cyclin D1 in 5 samples (17%) and phospho ERK in 17
(57%) without any correlation with PFS. It may be noted that none
of the patients with detectable cyclin D1 expression had progressed
at 1 year. No expression of M-CSFR, PDGFRA, E-Cadherin,
phospho MEK 1–2, or phospho Akt on ser 473 was observed.
Among the ten patients for whom DNA was available, we observed
one CR and one PR (response rate 2 out of 10, 20%) on imatinib and
8 (80%) disease stabilisations. Three (30%) tumours were found to
harbour the KIT exon 10 mutation, including the patient with CR
(13 months þ) and two patients with SD. One PR and six disease
stabilisations were observed in the other seven patients. PFS was not
significantly different in patients with and without KIT mutations,
nor between patients with and without DNA available for sequencing.
Other clinical and biological factors were also tested for correlation
with imatinib response in this series. Tumour size over 120mm was
associated with a worse PFS (median PFS, 5 months vs 15months,
P¼0.007). None of the other clinical characteristics tested (gender,
age, site of primary tumour, PS, number of previous surgeries), nor
PNN (neutrophil) count or haemoglobin levels before imatinib were
found correlated with PFS. Conversely, lymphopenia (o1500/ml)
before initiation of imatinib was found to be highly correlated with a
poorer PFS in this series (Figure 1B). Lymphopenia and tumour size
above 120mm were the only two parameters found significantly
predictive of adverse outcome using the Cox model (lymphopenia
HR¼38, P¼0.002; size4120mm HR¼19, P¼0.008).
DISCUSSION
Several studies have failed to explain the biological mechanisms
underlying the cytostatic effect of imatinib in AF. Heinrich et al
(2006) have investigated a series of 19 patients with AF treated with
imatinib and tested them for expression of several proteins (total
and activated KIT, PDGFRA and B, activated PI3K Akt, MAPK and
STAT3) and CTNNB1 mutations. However, they have failed to
identify factors predictive of response and outcome after imatinib
treatment, and no KIT expression by IHC or KIT mutation (exon 9,
11–13, 17 but not exon 10 were sequenced) has been detected.
Seinfeld et al (2006) have reported the detection of a KIT exon 10
germline variant resulting in M541L substitution in two of four
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Figure 1 (A) Progression-free survival of patients with (green),
without (blue) and with undetermined (black) KIT exon 10 mutation.
(B) Progression-free survival of lymphopenic (green) and non-lymphopenic
(blue) patients. (See online version for color information.)
Table 2 Patient and disease characteristics
N (40) %




PS (available for 37 patients)
02 7 7 3
19 2 4
21 3
Tumour location (multifocal in four cases)
Extraabdominal 28 70
Abdominal wall 7 18
Intraabdominal 8 20
Previous treatment before enrolment
Surgery 34 85
Radiotherapy (median dose 50Gy) 9 23
Hormonal therapy 18 45
Treatment with NSAID 12 30
Chemotherapy 8 20
Abbreviations: NSAID¼non-steroidal anti-inflammatory drug; PS¼performance
status.
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sextraabdominal AF samples. Some of us have later reported on a
patient with AF who responded to imatinib treatment and
presented with the same KIT exon 10 variant (Gonc¸alves et al,
2006). This is the reason why we searched for M541L exon 10
variant in our series of patients treated with imatinib.
To our knowledge, this is the largest series investigating pre-
imatinib tumour- and host-related molecular and clinical factors,
including KIT exon 10 mutations. Even though only a limited
number of cases could be investigated, response rates and PFS
were not found significantly different in patients with and without
the M541L KIT allele. It may be noted though, all three patients
with M541L allele achieved tumour control with imatinib,
including one patient with a CR. Even if not statistically confirmed,
the results of the present study strongly support the clinical
impression that AF patients harbouring the M541L variant are
more sensitive to imatinib. The lack of statistical correlation
between the presence of the M541L variant and response rate or
survival is probably because of the low number of patients tested.
This observation is of major interest and should be confirmed in
a larger series. Moreover, the biological rationale for such a
mechanism remains to be explored.
By examining cell models transfected with the exon 10 M541L
variant, Tamborini et al (2006) and Bertucci et al (2007) have
failed to show that the substitution could result in KIT activation
or inactivation and actually corresponded to a KIT polymorphism.
Both groups have concluded that the sensitivity of AF to imatinib
requires an alternative explanation and possibly involves an
autocrine mechanism, possibly associated with a hypersensitivity
to SCF, related to the induction of a ligand-independent
dimerisation induced by the exon 10 variant. The lack of
correlation between expression on IHC and outcome is fully
consistent with the previous report by Heinrich et al. Interestingly,
Tabone-Eglinger et al (2008) have shown that GIST-type KIT
mutations induce an activation-dependent alteration of normal
maturation and trafficking, resulting in the intracellular retention
of the activated kinase within the cell. Imatinib-induced inhibition
of the phosphorylation of immature and mature mutant KIT
proteins has resulted in the restoration of KIT expression at the
cell surface. They conclude that these observations likely account
for the absence of correlation between response to imatinib and
KIT expression using IHC and may deserve to be investigated in
other tyrosine kinase-activated tumours. More recently, another
KIT exon 10 mutation possibly linked to imatinib response in AF
has been identified, V530I (Kurtz et al, 2010).
The only biological parameter correlated with PFS in our
patients was pre-treatment lymphopenia, whereas anaemia and
PNN count had no predictive value (Figure 1A). Of note,
lymphopenia was not found correlated to PS in this series.
Imatinib has been previously reported to exert an anti-tumour
activity in animal models through the modulation of immune
response (Borg et al, 2004).
The present observation shows that a baseline biological
characteristic of the host, not of the tumour, is the major
parameter influencing response to imatinib in aggressive fibro-
matosis. Tumour characteristics, including the presence of the KIT
exon 10 M541L variant, may have influenced tumour control in
this small series but this needs to be confirmed and better
explained.
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